Vanguard (DGX) amends 13G, reports 0 shares after Jan 12, 2026 realignment
Rhea-AI Filing Summary
The Vanguard Group amended its Schedule 13G for Quest Diagnostics Inc. The filing states that, following an internal realignment described in the filing, The Vanguard Group reports 0 shares beneficially owned of Quest Diagnostics common stock and 0% of the class as of 03/13/2026. The amendment explains that certain subsidiaries and business divisions will report holdings separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Positive
- None.
Negative
- None.
Insights
Vanguard disaggregated holdings and reports zero beneficial ownership after internal realignment.
The filing documents an internal realignment effective January 12, 2026 and relies on SEC Release No. 34-39538 for disaggregated reporting. It explicitly lists 0 shares and 0% beneficial ownership of Quest Diagnostics common stock in the amendment.
This is an administrative ownership disclosure reflecting reporting structure changes rather than a purchase or sale. Subsequent filings from Vanguard or the named subsidiaries may show separate beneficial positions for related entities.
FAQ
What does Vanguard's Schedule 13G/A for Quest Diagnostics (DGX) state?
Why did The Vanguard Group change its reporting for DGX?
Does the amendment show any Vanguard subsidiary owning Quest Diagnostics shares?
Who signed the Schedule 13G/A amendment for Vanguard and when?